

## *Short Communication*

# One-Pot Three-Component Synthesis of 3-Aminoimidazo[1,2-*a*]pyridines and -pyrazines in the Presence of Silica Sulfuric Acid

Ahmad Shaabani\*, Ebrahim Soleimani, and Ali Maleki

Department of Chemistry, Shahid Beheshti University, Tehran, Iran

Received July 24, 2006; accepted (revised) August 4, 2006  
Published online December 8, 2006 © Springer-Verlag 2006

**Summary.** The synthesis of 3-aminoimidazo[1,2-*a*]pyridines and 3-aminoimidazo[1,2-*a*]pyrazines through a condensation reaction of 2-aminopyridine or 2-aminopyrazine, aldehyde, and alkyl or aryl isocyanide in high yields at room temperature in the presence of silica sulfuric acid is described.

**Keywords.** Multi-component reaction; Isocyanide; 3-Aminoimidazo[1,2-*a*]pyridine; 3-Aminoimidazo[1,2-*a*]pyrazine; Silica sulfuric acid.

## Introduction

The imidazo[1,2-*a*]pyridine and imidazo[1,2-*a*]pyrazine moieties constitute a class of biologically active compounds that are potentially anti-inflammatory [1], anti-bacterial agents [2], inhibitors of gastric acids secretion [3], calcium channel blockers [4], and sedative-hypnotic drugs, such as *Zolpidem* and *Alpidem* [5].

The conventional two-component synthesis of imidazo[1,2-*a*]pyridines and imidazo[1,2-*a*]pyrazines, requires lachrymatory  $\alpha$ -haloketones and the corresponding 2-aminopyridines [6], which restricts the generation of a diverse ensemble of these molecules. Among the existing multi-component reactions (MCRs) available, one involves the condensation of an aldehyde, an isocyanide, and a 2-aminopyridine in the presence of homogeneous protic acids, such as *AcOH*, *HClO<sub>4</sub>*, and the *Lewis* acid *Sc(OTf)<sub>3</sub>* [7]. In spite of their potential utility, these catalysts present limitations due to the use of toxic and corrosive reagents, the tedious work-up procedure, and the necessity of neutralization of the strong acid media producing

---

\* Corresponding author. E-mail: a-shaabani@cc.sbu.ac.ir



**Table 1.** Synthesis of 3-aminoimidazo[1,2-*a*]pyridines and -pyrazines in the presence of silica sulfuric acid

| Product   | <i>R</i> <sup>1</sup>                            | <i>R</i> <sup>2</sup> | <i>R</i> <sup>3</sup>  | <i>X</i> | Yield/%                           |
|-----------|--|-----------------------|--|----------|-----------------------------------|
| <b>4a</b> | <i>Ph</i>  | Br                    | Cyclohexyl   | CH       | (98, 95, 92, 90, 85) <sup>a</sup> |
| <b>4b</b> | <i>Ph</i>  | <i>Me</i>             | Cyclohexyl   | CH       | 95                                |
| <b>4c</b> | 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>  | <i>Me</i>             | Cyclohexyl   | CH       | 99                                |
| <b>4d</b> | 4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub> | H                     | Cyclohexyl   | N        | 90                                |
| <b>4e</b> | 4-ClC <sub>6</sub> H <sub>4</sub>                | <i>Me</i>             | Cyclohexyl   | CH       | 85                                |
| <b>4f</b> | 3-O <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>  | <i>Me</i>             | Cyclohexyl   | CH       | 90                                |
| <b>4g</b> | 4-pyridyl  | <i>Me</i>             | Cyclohexyl   | CH       | 91                                |
| <b>4h</b> | <i>Ph</i>  | Br                    | <i>tert</i> -Butyl   | CH       | 97                                |
| <b>4i</b> | <i>Ph</i>  | <i>Me</i>             | <i>tert</i> -Butyl   | CH       | 99                                |
| <b>4j</b> | 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>  | <i>Me</i>             | <i>tert</i> -Butyl   | CH       | 98                                |
| <b>4k</b> | 4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub> | H                     | <i>tert</i> -Butyl   | N        | 85                                |
| <b>4l</b> | <i>Ph</i>  | <i>Me</i>             | 2,6-( <i>Me</i> ) <sub>2</sub> C <sub>6</sub> H <sub>3</sub> | CH       | 77                                |
| <b>4m</b> | 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>  | <i>Me</i>             | 2,6-( <i>Me</i> ) <sub>2</sub> C <sub>6</sub> H <sub>3</sub> | CH       | 81                                |

<sup>a</sup> The same catalyst recovered and reused for each of the five runs

methylpyridine, 2-amino-5-bromopyridine, or 2-aminopyrazine, and alkyl or aryl isocyanide in the presence of the silica based solid acid catalyst. Solid acids are environmentally friendly with respect to corrosiveness, safety, waste, and ease of separation and recovery. Thus, replacement of liquid acids with solid acids is desirable in the chemical industry.

## Experimental

Melting points were measured on an Electrothermal 9200 apparatus. IR spectra were recorded on a FT-IR 102MB BOMEM apparatus. Mass spectra were recorded on a FINNIGAN-MAT 8430 mass spectrometer operating at an ionization potential of 70 eV. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a BRUKER DRX-300 AVANCE spectrometer at 300.13 and 75.47 MHz. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained on solutions in CDCl<sub>3</sub> and DMSO-*d*<sub>6</sub>. 2-Amino-5-methylpyridine, 2-amino-5-bromopyridine or 2-aminopyrazine, isocyanides, and aldehydes were purchased from Fluka and Merck and used without purification.

All products (except **4d** and **4k**) are known compounds [12 g], which were characterized by melting point, IR, <sup>1</sup>H and <sup>13</sup>C NMR spectral data, and mass spectroscopy.

### General Procedure

To a solution of 1 mmol 2-aminoazine, 1.2 mmol aldehyde, and 1.1 mmol alkyl or aryl isocyanide in methanol (4 cm<sup>3</sup>) was added a catalytic amount of 0.11 g silica sulfuric acid prepared according to Ref. [10]. The resulting mixture was stirred for 3 h at room temperature. After completion of the reaction, as indicated by TLC (ethyl acetate/*n*-hexane, 2/1), the solid catalyst was separated by filtration. The solvent was evaporated under reduced pressure and after washing the residue with ethyl acetate the products were obtained.

### *N*-Cyclohexyl-2-(4-methoxyphenyl)imidazo[1,2-*a*]pyrazin-3-amine (**4d**, C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O)

Yellow crystals (0.290 g, 90%); mp 198–199°C (dec); IR (KBr):  $\bar{\nu}$  = 3225, 2910, 1636, 1603 cm<sup>-1</sup>; MS: *m/z* (%) = 322 (M<sup>+</sup> + 1, 21), 321 (M<sup>+</sup>, 62), 319 (75), 209 (100), 92 (64), 65 (50), 55 (36), 31 (29); <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 1.12–1.76 (m, 5CH<sub>2</sub>-cyclohexyl), 3.04 (m, CH-N-cyclohexyl), 3.84

(s, OCH<sub>3</sub>), 3.80–3.90 (bs, NH), 6.95–8.96 (m, H–Ar) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 24.88, 25.33, 34.11 (C–cyclohexyl), 55.34 (OCH<sub>3</sub>), 56.23 (CH–N–cyclohexyl), 114.24, 117.73, 123.59, 126.74, 128.61, 129.05, 134.61, 139.61, 140.86, 160.51 (C–Ar) ppm.

*N*-tert-Butyl-2-(4-methoxyphenyl)imidazo[1,2-*a*]pyrazin-3-amine (**4k**, C<sub>17</sub>H<sub>20</sub>N<sub>4</sub>O)

Yellow crystals (0.25 g, 85%); mp 165–168°C (dec); IR (KBr):  $\bar{\nu}$  = 3275, 2850, 1644, 1606 cm<sup>-1</sup>; MS: *m/z* (%) = 296 (M<sup>+</sup> + 1, 19), 295 (M<sup>+</sup>, 32), 209 (100), 92 (67), 65 (34), 57 (23); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>): δ = 1.04 (s, C(CH<sub>3</sub>)<sub>3</sub>), 3.79 (s, OCH<sub>3</sub>), 3.84 (bs, NH), 6.89 (d, *J* = 8.6 Hz, H–Ar), 7.94 (d, *J* = 8.6 Hz, H–Ar), 7.99–9.17 (m, H–Ar) ppm; <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>): δ = 30.34 (C(CH<sub>3</sub>)<sub>3</sub>), 55.26 (C(CH<sub>3</sub>)<sub>3</sub>), 57.27 (OCH<sub>3</sub>), 113.95, 117.44, 123.30, 126.45, 128.33, 129.69, 134.32, 139.32, 140.58, 160.26 (C–Ar) ppm.

## Acknowledgement

We gratefully acknowledge the financial support from the Research Council of Shahid Beheshti University.

## References

- [1] a) Maruyama Y, Anami K, Terasawa M, Goto, K, Imayoshi T, Kadobe Y, Mizushima Y (1981) *Arzneimittel-Forsch* **31**: 1111; b) Maruyama Y, Anami K, Katoh Y (1978) *Arzneimittel-Forsch* **28**: 2102
- [2] Rival Y, Grassy G, Michel G (1992) *Chem Pharm Bull* **40**: 1170
- [3] Kaminski JJ, Wallmark B, Briving C, Andersson BM (1991) *J Med Chem* **34**: 533
- [4] Sanfilippo PJ, Urbanski M, Press JB, Dubinsky B, Moore JB (1988) *J Med Chem* **31**: 2221
- [5] Trapani G, Franco M, Ricciardi L, Latrofa A, Genchi G, Sanna E, Tuveri F, Cagetti E, Biggio G, Liso G (1997) *J Med Chem* **40**: 3109
- [6] a) Sablayrolles C, Cros GH, Milhavet JC, Rechenq E, Chapat JP, Boucard M, Serrano JJ, McNeill JH (1984) *J Med Chem* **27**: 206; b) Spitzer WA, Victor F, Pollock DG, Hayers JS (1988) *J Med Chem* **31**: 1590; c) Blewitt HL (1977) In: Weissberger A, Taylor EC (eds) *Special Topics in Heterocyclic Chemistry*. Wiley, New York, p 117
- [7] a) Blackburn C, Guan B, Fleming P, Shiosaki K, Tsai S (1998) *Tetrahedron Lett* **39**: 3635; b) Bienayme H, Bouzid K (1998) *Angew Chem Int Ed* **37**: 2234; c) Groebke K, Weber L, Mehlin F (1998) *Synlett* 661; d) Blackburn C (1998) *Tetrahedron Lett* **39**: 5469; e) Mandair GS, Light M, Russell A, Hursthouse M, Bradley M (2002) *Tetrahedron Lett* **43**: 4267
- [8] Varma RS, Kumar D (1999) *Tetrahedron Lett* **40**: 7665
- [9] Ireland SM, Tye H, Whittaker M (2003) *Tetrahedron Lett* **44**: 4369
- [10] Zolfigol MA (2001) *Tetrahedron* **57**: 9509
- [11] a) Shaabani A, Bazgir A, Teimouri F, Lee DG (2002) *Tetrahedron Lett* **43**: 5165; b) Shaabani A, Soleimani K, Bazgir A (2004) *Synth Commun* **34**: 3303; c) Shaabani A, Teimouri F, Lee DG (2003) *Synth Commun* **33**: 1057; d) Shaabani A, Lee DG (2003) *Synth Commun* **33**: 1255
- [12] a) Shaabani A, Soleimani E, Khavasi HR, Hoffmann RD, Rodewald UC, Poettgen R (2006) *Tetrahedron Lett* **47**: 5493; b) Shaabani A, Teimouri MB, Arab Ameri S (2004) *Tetrahedron Lett* **45**: 8409; c) Shaabani A, Teimouri MB, Bijanzadeh HR (2002) *Tetrahedron Lett* **43**: 9151; d) Shaabani A, Yavari I, Teimouri MB, Bazgir A, Bijanzadeh HR (2001) *Tetrahedron* **57**: 1375; e) Shaabani A, Teimouri MB, Bazgir A, Bijanzadeh HR (2003) *Mol Div* **6**: 199; f) Shaabani A, Teimouri MB, Bijanzadeh HR (2004) *Monatsh Chem* **135**: 441; g) Shaabani A, Soleimani E, Maleki A (2006) *Tetrahedron Lett* **47**: 3031; h) Shaabani A, Teimouri MB, Bijanzadeh HR (2003) *J Chem Res (S)* 578